EGFR and Diarrhea: Gastrointestinal AEs, particularly diarrhea, are common with many classes of anticancer therapy, including EGFR and MET inhibitors, and have a substantial impact on quality of life.43,44,90 Diarrhea was reported in up to 95% of patients on first- and second-generation EGFR TKIs and in up to 58% of patients on osimertinib.44 In amivantamab trials, diarrhea was reported in 12% of patients receiving amivantamab monotherapy, 14%-21% receiving amivantamab plus chemotherapy, and 29% receiving amivantamab plus lazertinib.21,28,32,40